Guggenheim Capital’s Soleno Therapeutics SLNO Stock Holding History

Guggenheim Capital’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-24,326	Closed	-$814K	–	1768
2026 Q1	$814K	Buy	24,326 +6,145	+34%	+$241K	0.01%	1055
2025 Q4	$842K	Buy	18,181 +8,713	+92%	+$478K	0.01%	1023
2025 Q3	$640K	Buy	+9,468	New	+$702K	﹤0.01%	1086

Guggenheim Capital's SLNO Position: Q2 2026 in Review

Guggenheim Capital sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 24,326 shares — an estimated $814K sold.

Guggenheim Capital first reported a position in SLNO in Q3 2025 and held it in 3 quarters. The position peaked at $842K in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Guggenheim Capital reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Guggenheim Capital sold 24,326 Soleno Therapeutics shares in Q2 2026, an estimated $814K.
Guggenheim Capital first reported a position in Soleno Therapeutics in Q3 2025 and held it in 3 quarters.
Guggenheim Capital's Soleno Therapeutics position peaked at $842K in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.